Scientists test adding a targeted drug to standard cervical cancer treatment
NCT ID NCT00957411
Summary
This study tested if adding a targeted drug called cetuximab to the standard treatment of radiation and chemotherapy (cisplatin) was better for controlling cervical cancer. It involved 76 women with stage IB2, II, or IIIB cervical cancer who were not eligible for immediate surgery. The main goal was to see if the combination kept more patients cancer-free for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie Hopital
Paris, 75248, France
Conditions
Explore the condition pages connected to this study.